Financial Data and Key Metrics Changes - Total company net sales for Q1 2021 were $14.7 million, a 2% increase year-over-year, despite supply chain disruptions [9][21][29] - Gross margins improved to approximately 62.9%, up from 61% in Q4 2020 [21][25] - Adjusted EBITDA, excluding legal expenses, was a loss of approximately $0.7 million, showing a $2.4 million improvement from the prior quarter [9][21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 17% compared to Q1 2020, indicating strong demand for Tru Niagen [9][29] - Sales to Watson's were $1.6 million in Q1 2021, down from $2.1 million in the prior quarter due to supply chain issues [21][23] - Ingredient sales were $1.2 million, down from $2.2 million in the previous quarter, attributed to the loss of a customer [23][24] Market Data and Key Metrics Changes - The company signed over 230 research collaboration agreements, representing over $75 million in investments from external research institutions [10] - The demand for Tru Niagen remains strong, with expectations for increased sales in the upcoming quarters [15][29] Company Strategy and Development Direction - The company aims to expand its market presence through strategic partnerships with Walmart, H&H Group, and Row, focusing on product launches and brand awareness [8][12][34] - Management is optimistic about future growth, emphasizing the importance of protecting intellectual property and expanding scientific research [10][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged supply chain disruptions but expressed confidence in resolving these issues and meeting future demand [9][62] - The company expects steady revenue growth and anticipates an acceleration in sales growth beginning in Q2 2021 [33][34] Other Important Information - The company ended Q1 2021 with $44.7 million in cash, including a $25 million capital raise in February [22][31] - Legal expenses increased significantly due to ongoing litigation, but management expects this to stabilize moving forward [27][30] Q&A Session Summary Question: What more can you tell us about the Walmart rollout? - Management indicated that marketing efforts will gradually increase, with a focus on brand awareness and in-store promotions [36][37] Question: Will Tru Niagen be available globally through the H&H Group agreement? - The agreement is initially limited to specific regions, with plans for unique formulations and a launch expected in Q4 2021 [38] Question: Why was there no Nestle revenue in Q1? - Management confirmed that the slow rollout of Nestle's Celltrient product was anticipated, and they expect the relationship to expand over time [40][41] Question: What will the financials look like for the H&H Group agreement? - The agreement is a conventional supply deal without royalties, focusing on a price per kilogram [43] Question: How is the HCP segment performing post-restrictions? - Management sees the HCP market as a growth area and plans to invest more in educating healthcare practitioners about the benefits of Tru Niagen [49] Question: What are the expectations for margins throughout 2021? - Management expects margins to remain slightly above 60% for 2021, with potential improvements as sales increase [50]

Financial Performance - For the three-month period ending March 31, 2021, net sales were $14.683 million, a 2% increase compared to $14.345 million for the same period in 2020[137]. - The consumer products segment, primarily driven by TRU NIAGEN®, saw sales increase by 12% to $12.437 million from $11.144 million year-over-year[142]. - The ingredients segment experienced a 47% decline in sales, dropping to $1.315 million from $2.475 million, largely due to the loss of a key customer[142][146]. - The net loss for the three-month period ending March 31, 2021, was $7.381 million, compared to a net loss of $5.902 million for the same period in 2020[137]. - Total gross profit for the company increased by 11% to $9.2 million compared to $8.3 million in the prior year[153]. Cost and Expenses - Cost of sales as a percentage of net sales decreased by 5% to 37% for the three-month period ending March 31, 2021, compared to 42% for the same period in 2020[149]. - The cost of sales for the consumer products segment decreased by 5% as a percentage of net sales, attributed to product mix and cost savings initiatives[149]. - The analytical reference standards and services segment saw a 20% decrease in cost of sales as a percentage of net sales, reflecting improved labor and overhead utilization[151]. - Sales and marketing expenses rose by 41% to $6.3 million from $4.4 million, driven by increased direct marketing efforts and staffing in the consumer products segment[159]. - Research and development expenses decreased by 10% to $0.8 million from $0.9 million, reflecting a realignment of ongoing projects[163]. - General and administrative expenses increased by 8% to $9.5 million, largely due to a rise in legal expenses from $2.4 million to $5.0 million[164]. Cash Flow and Financing - As of March 31, 2021, the company had approximately $44.7 million in cash and cash equivalents, with an additional line of credit of up to $7.0 million available[135]. - The company successfully raised $24.9 million through the sale of approximately 3.8 million shares at $6.50 per share in February 2021[133]. - Net cash used in operating activities was approximately $5.4 million for the three months ended March 31, 2021, compared to $5.2 million in the same period in 2020[177]. - Net cash provided by financing activities was approximately $33.4 million for the three months ended March 31, 2021, significantly higher than $37,000 in the prior year[181]. Operational Challenges - The company maintains adequate inventory levels to support growth despite supply chain disruptions caused by COVID-19[130]. - The ingredients segment experienced a gross profit decline of 47%, down to $0.8 million from $1.4 million year-over-year, primarily due to lower sales[156]. - The company has incurred aggregate losses of approximately $149.2 million since inception, primarily due to operational expansion and litigation-related expenses[171]. Tax and Internal Control - The effective tax rate for the three-month periods ended March 31, 2021, and March 31, 2020, was approximately 0% due to a full valuation allowance against deferred tax assets[166]. - No changes in internal control over financial reporting occurred during the Company's first fiscal quarter that materially affected or are likely to materially affect internal control[191]. - A material weakness in internal control over financial reporting was addressed during the last fiscal quarter[190].

ChromaDex Earnings Conference Call Fourth Quarter 2020 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | March 10, 2021 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 26-2940963 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share CDXC The Nasdaq Capital Market Large accelerated filer ☐ Non-accelerated filer ☒ Accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...

Financial Data and Key Metrics Changes - Total company sales grew 9% sequentially and 18% year-over-year, with total net sales nearly $60 million and Tru Niagen net sales at $47 million for the year [10][27] - Adjusted EBITDA for Q4 2020 was a loss of $1.1 million, improving by $1 million year-over-year, with a full-year loss of $1 million compared to $8.8 million in 2019 [11][41] - Gross margins increased to 61%, up approximately 400 basis points year-over-year [28][39] Business Line Data and Key Metrics Changes - Tru Niagen net sales grew 31% year-over-year, with e-commerce sales up 20% [27][38] - Niagen ingredient sales more than doubled in Q4 to $2.2 million compared to $0.9 million in the previous quarter [32] Market Data and Key Metrics Changes - Tru Niagen will soon be available in 3,000 Walmart stores across the U.S., expanding the distribution footprint significantly [14] - The company has established partnerships with major players like A.S. Watson Group and Nestlé Health Science, enhancing market presence [13] Company Strategy and Development Direction - The company aims to achieve cash flow break-even while expanding scientific research on Niagen and increasing marketing investments [11][17] - Focus on building a global brand and exploring new retail partnerships while maintaining a careful and selective approach to collaborations [83] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting strong scientific research and a growing body of evidence supporting Niagen's health benefits [12][26] - The addressable market for Niagen is large, with increasing consumer awareness and a commitment to long-term value creation [17][29] Other Important Information - The company ended the year with $16.7 million in cash and raised an additional $25 million in February 2021 [29][42] - Significant investments in R&D are planned to develop new formulations and delivery mechanisms for existing products [68][69] Q&A Session Summary Question: Details on Walmart partnership and stocking - The company plans to offer a lower dose and price point for Walmart, with a focus on creating awareness through marketing [47] Question: COVID-19 trial in Turkey - Management discussed ongoing studies related to COVID-19 and the potential of Tru Niagen, noting the differences in standard of care between Turkey and the U.S. [50][51] Question: Changes in marketing strategy for 2021 - The company will continue using influencers while targeting different customer cohorts with tailored marketing channels [65][66] Question: Future retail partnerships - While there are no immediate plans for additional retail partnerships, the company remains open to opportunities that align with its strategic goals [83]

Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer TRU NIAGEN® Nasdaq: CDXC | December 2020 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements reflect the current view about future events. Sta ...

ChromaDex Corporation (NASDAQ:CDXC) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Brianna Gerber – Vice President-FP&A and Investor Relations Rob Fried – Chief Executive Officer Frank Jaksch – Co-Founder and Executive Chairman Kevin Farr – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Brian Nagel – Oppenheimer Jeff Van Sinderen – B. Riley FBR Ram Selvaraju – H.C. Wainwright Mitchell Pinheiro – Sturdivant & Company JP Mark – Farmhouse Equit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State incorporation or (I.R.S. Employer Identification No.) orotherjurisdictionof organization) 10900 Wilshire Blvd. Suite 600, Los Angeles, CA (Address of Pr ...

ChromaDex Corporation (NASDAQ:CDXC) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Brianna Gerber - Vice President, FP&A & Investor Relations Rob Fried - Chief Executive Officer Frank Jaksch - Founder & Executive Chairman Kevin Farr - Chief Financial Officer Conference Call Participants Jeff Vansen Sinderen - B. Riley Brian Nagel - Oppenheimer Mitchell Pinheiro - Sturdivant JP Mark - Farmhouse Equity Research Matt Dhane - Tieton Capital Management Operator Ladies and gentlem ...

ChromaDex Earnings Conference Call Second Quarter 2020 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | August 6, 2020 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-l ...